| Detected | Trial | Change |
|---|---|---|
| 2026-08-07 | NCT07223814 Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by… |
Trial sites expanded: 43 -> 63 locations |
| 2026-07-30 | NCT06652438 Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or… |
Primary endpoint(s) modified |
| 2026-07-30 | NCT06652438 Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or… |
Trial sites expanded: 67 -> 201 locations |
| 2026-07-30 | NCT06652438 Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or… |
date change Completion pushed: 2031-07-10 -> 2032-08-27 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06187441 | FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With… | Multiple Myeloma | Recruiting |
| NCT07075016 | Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly… | Acute Myeloid Leukemia | Recruiting |
| NCT06220032 | Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With… | DLBCL - Diffuse Large B Cell Lymphoma | Recruiting |
| NCT06652438 | Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or… | Acute Myeloid Leukemia, Adult | Recruiting |
| NCT07223814 | Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by… | Acute Myeloid Leukemia | Recruiting |
| NCT03839771 | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and… | Acute Myeloid Leukemia | Active, Not Recruiting |
| NCT04027309 | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and… | Acute Myeloid Leukemia | Active, Not Recruiting |
| Phase 2 | |||
| NCT06014489 | A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult… | AML, Adult | Recruiting |
| NCT04523428 | REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) | CLL/SLL | Recruiting |
| NCT04639362 | CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and… | CLL | Active, Not Recruiting |
| NCT03645824 | Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) | Myelofibrosis | Active, Not Recruiting |
| NCT03673826 | Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in… | Smouldering Myeloma | Active, Not Recruiting |
| NCT03620578 | DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2… | Non Hodgkin Lymphoma | Active, Not Recruiting |
| NCT03541083 | Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute… | ALL, Adult | Active, Not Recruiting |
| NCT04097470 | Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High… | AML/MDS | Active, Not Recruiting |
| NCT03463057 | The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High… | NHL | Active, Not Recruiting |
| NCT05502250 | Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab… | Hodgkin Lymphoma | Active, Not Recruiting |
| NCT06067048 | Zanubrutinib in Primary Cold Agglutinin Disease | Lymphoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT03356054 | Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to… | DLBCL | Recruiting |
| NCT05791409 | Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients… | CLL/SLL | Recruiting |
| NCT06605586 | Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition | Myelofibrosis | Recruiting |